SCHEMBL16640336

SCHEMBL16640336

CC(C)n1c2ccncc2c2ccncc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 3/20 0.45
NFATC1 O95644 2/20 0.45
GSK3B P49841 2/20 0.45
USP2 O75604 1/20 0.42
HTT P42858 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
MAOA P21397 5/20 0.40
MAOB P27338 5/20 0.40
ACHE P22303 2/20 0.40
KCNH2 Q12809 1/20 0.39
CYP2D6 P10635 1/20 0.38
CDK4 P11802 2/20 0.37
METAP2 P50579 1/20 0.35
NPY5R Q15761 1/20 0.34
CDK6 Q00534 1/20 0.34
BCHE P06276 1/20 0.34
UTS2R Q9UKP6 1/20 0.34
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16640345 0.92 USP2 (0.46) DYRK1ANFATC1GSK3BUSP2HTT
SCHEMBL16640338 0.92 DYRK1A (0.50) DYRK1ANFATC1GSK3BUSP2HTT
SCHEMBL16640343 0.87 MAOA (0.54) USP2HTTNCOA1NCOA3MAOA
SCHEMBL16640344 0.87 ACHE (0.46) DYRK1ANFATC1GSK3BUSP2HTT
SCHEMBL2719167 0.80 CHUK (0.42) DYRK1ANFATC1GSK3BUSP2HTT
SCHEMBL12464508 0.78 MAOA (0.51) HTTMAOAMAOBACHECYP2D6
SCHEMBL14665591 0.77 NPY5R (0.43) DYRK1ANFATC1GSK3BKCNH2CDK4
SCHEMBL25467587 0.75 DYRK1A (0.40) DYRK1ANFATC1GSK3BUSP2HTT
SCHEMBL16640349 0.75 USP2 (0.43) DYRK1ANFATC1GSK3BUSP2HTT
SCHEMBL16640326 0.75 USP2 (0.40) DYRK1ANFATC1GSK3BUSP2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11189808-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-11-30 US disclosed
US-20200152891-A1 PLATINUM COMPLEXES AND DEVICES UNIV ARIZONA STATE (US) 2020-05-14 US disclosed
US-9947881-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-17 US disclosed
US-20170012224-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2017-01-12 US disclosed
US-9385329-B2 Platinum complexes and devices Arizona Board of Regents on behalf of Arizona State University and Universal Display Corporation (US) 2016-07-05 US disclosed
US-20150105556-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11189808-B2 Platinum complexes and devices OXA1L, OCIAD1, OCIAD2 DYRK1A 4759/4885NFATC1 4160/4885GSK3B 3944/4885
US-20200152891-A1 PLATINUM COMPLEXES AND DEVICES OXA1L, OCIAD1, OCIAD2 DYRK1A 4759/4885NFATC1 4160/4885GSK3B 3944/4885
US-20170012224-A1 PLATINUM COMPLEXES AND DEVICES OXA1L, OCIAD1, OCIAD2 DYRK1A 4759/4885NFATC1 4160/4885GSK3B 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.